41171-91-9

Basic information

• Product Name: 3-Oxo-cyclopentanecarbonitrile
• Synonyms: 3-Oxo-cyclopentanecarbonitrile;3-Oxocyclopentane-1-Carbonitrile
• CAS NO: 41171-91-9
• Molecular Formula: C₆H₇NO
• Molecular Weight: 109.12588
• Mol File: 41171-91-9.mol

Chemical Properties

• Boiling Point: 250-270 °C(Press: 1 Torr)
• Appearance: /
• Density: 1.08±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Oxo-cyclopentanecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Oxo-cyclopentanecarbonitrile(41171-91-9)
• EPA Substance Registry System: 3-Oxo-cyclopentanecarbonitrile(41171-91-9)

Safety Data

• Hazardous Substances Data: 41171-91-9(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
3-Oxo-cyclopentanecarbonitrile is utilized as an intermediate in the synthesis of various organic compounds, particularly in the pharmaceutical and chemical industries. Its unique structure allows for further functionalization and modification, making it a valuable building block for the development of new molecules with specific properties and applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-Oxo-cyclopentanecarbonitrile is used as a key intermediate in the synthesis of various drug molecules. Its reactivity and structural diversity enable the development of novel therapeutic agents with improved efficacy and selectivity.
Used in Catalytic Enantioselective Conjugate Addition:
3-Oxo-cyclopentanecarbonitrile is employed as a reactant in the catalytic enantioselective conjugate addition of cyanide to enones. This process is crucial for the synthesis of chiral molecules with high enantiomeric purity, which are essential in the development of enantiomerically pure drugs and other biologically active compounds.

Synthesis Reference(s)

The Journal of Organic Chemistry, 38, p. 3455, 1973 DOI: 10.1021/jo00960a002

Upstream product

• 930-30-3 cyclopent-2-enone 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 151-50-8 potassium cyanide 
• 120-92-3 cyclopentanone 
• 19158-51-1 P-toluenesulfonyl cyanide 
• 773837-37-9 sodium cyanide 
• 7677-24-9 trimethylsilyl cyanide 
• 98098-46-5 3-cyano-1-diethylphosphonooxy-1-cyclopentene 
• 15760-35-7 3-methylenecyclobutanecarbonitrile 

Downstream Products

• 159329-38-1 3,3-ethylenedioxycyclopentanecarbonitrile 
• 194534-83-3 3-hydroxycyclopentane-carbonitrile 
• 24056-33-5 3-hydroxycyclohexanecarbonitrile 
• 373826-61-0 N-3-cyanocyclopentyl-4-(2-(3-amino-phenoxy)ethyl)morpholine 
• 163559-78-2 3-(diphenylhydroxymethyl)cyclopentanone ethylene ketal 
• 163559-76-0 3-benzoylcyclopentanone ethylene ketal 
• 163559-77-1 3-phenethylcyclopent-2-en-1-one 
• 21414-81-3 cis-5,6-diphenylbicyclo<3.1.0>hexan-2-one 
• 21414-81-3 trans-5,6-diphenylbicyclo<3.1.0>hexan-2-one 
• 70239-00-8 3-benzhydrylcyclopent-2-en-1-one 
• 182298-14-2 3-Benzyl-3-(4-methyl-benzoyl)-cyclopentanone 
• 182298-12-0 3-(3-Methoxy-benzoyl)-cyclopentanone 

Relevant articles and documents

Direct C(sp3)-H Cyanation Enabled by a Highly Active Decatungstate Photocatalyst

A highly efficient, direct C(sp3)-H cyanation was developed under mild photocatalytic conditions. The method enabled the direct cyanation of various C(sp3)-H substrates with excellent functional group tolerance. Notably, complex natural products and bioactive compounds were efficiently cyanated.

Chiral Cyclic Aliphatic Linkers as Building Blocks for Selective Dopamine D2or D3Receptor Agonists

Linkers are emerging as a key component in regulating the pharmacology of bitopic ligands directed toward G-protein coupled receptors (GPCRs). In this study, the role of regio- and stereochemistry in cyclic aliphatic linkers tethering well-characterized primary and secondary pharmacophores targeting dopamine D2 and D3 receptor subtypes (D2R and D3R, respectively) is described. We introduce several potent and selective D2R (rel-trans-16b; D2R Ki = 4.58 nM) and D3R (rel-cis-14a; D3R Ki = 5.72 nM) agonists while modulating subtype selectivity in a stereospecific fashion, transferring D2R selectivity toward D3R via inversion of the stereochemistry around these cyclic aliphatic linkers [e.g., (-)-(1S,2R)-43 and (+)-(1R,2S)-42]. Pharmacological observations were supported with extensive molecular docking studies. Thus, not only is it an innovative approach to modulate the pharmacology of dopaminergic ligands described, but a new class of optically active cyclic linkers are also introduced, which can be used to expand the bitopic drug design approach toward other GPCRs.

D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF

Disclosed herein are novel compounds including dopamine D3 receptor agonists, compositions thereof, methods of use thereof, and processes of synthesizing the same. Further disclosed are D3R selective agonist compounds, specifically bitopic ligands comprising chirality.

Facile synthesis of 2-azaspiro[3.4]octane

Our annulation strategy utilized for the synthesis of 2-azaspiro[3.4]octane is explained. Three successful routes for the synthesis were developed. One of the approaches involved annulation of the cyclopentane ring and the remaining two approaches involved annulation of the four membered ring. All three approaches employ readily available starting materials with conventional chemical transformations and minimal chromatographic purifications to afford the title compound. The merits and limitations of the three approaches are also discussed.

Preparation of chiral 3-oxocycloalkanecarbonitrile and its derivatives by crystallization-induced diastereomer transformation of ketals with chiral 1,2-diphenylethane-1,2-diol

Chiral 3-oxocycloalkanecarbonitriles were prepared by fractional crystallization and crystallization-induced diastereomer transformation (CIDT) of diastereomeric ketals with (1R,2R)-1,2-diphenylethane-1,2-diol. Investigation of the crystal structures by X

Glutaminase inhibitors as well as compositions and applications thereof

The invention provides a series of heterocyclic compounds expressed in a formula I. The compound comprises glutaminase inhibition activity, and can be used for treating diseases and symptoms related to dysfunction of glutaminase or raising activity of glutaminase.

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.

2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use

In its many embodiments, the present invention provides certain iminothiazine dioxide compounds, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, wherein each of the variables shown in the formula are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer's disease, are also disclosed.

HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, R4, R5, n, m, p and X are as defined in the description, their preparation and their use as pharmaceutically active compounds.

FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES

The invention provides novel compounds of formula (I) having the general formula (I) wherein R1, V, W, X, Y and Z are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.